Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer therapy, with its Chief Medical Officer, Dr. Islam Mohamed, outlining the potential of the company's lead drug candidate ONC010 in a recent BioMedWire Podcast. The discussion centered on ONC010's unique targeting of the DNA repair enzyme polynucleotide kinase phosphatase (PNKP), a novel clinical target in the DNA damage response pathway, and the company's planned first-in-human clinical program.
Dr. Mohamed emphasized two key selectivity mechanisms that distinguish ONC010. First, the drug employs synthetic lethality, a strategy designed to limit its lethal effects to cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins. This means the drug should preferentially kill cancer cells with these specific genetic defects while sparing healthy cells. Second, ONC010 uses nanoparticle delivery intended to concentrate the drug within tumor tissue, potentially enhancing efficacy and reducing systemic toxicity. These mechanisms collectively aim to improve the therapeutic index of the treatment.
Preclinical research conducted at the University of Alberta further supports ONC010's potential. In these studies, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. Such results are encouraging as they suggest that ONC010 could be effective as a monotherapy, a rare attribute in oncology, and may offer a new option for patients with limited treatment alternatives.
The significance of this announcement lies in its potential to address unmet needs in cancer treatment. PNKP is an emerging target, and Onco-Innovations holds an exclusive worldwide licence to patented technology directed to its therapeutic inhibition. If successful in clinical trials, ONC010 could represent a first-in-class therapy for cancers characterized by PTEN or SHP-1 deficiencies, which are common in various tumor types. This could open new avenues for personalized cancer treatment.
Moreover, the planned first-in-human clinical program marks a critical step in translating preclinical promise into clinical reality. Investors and industry observers will be watching closely as Onco-Innovations progresses toward testing in humans, which will provide essential data on safety, dosing, and early efficacy signals. Success in these trials could significantly enhance the company's value and attract partnership interest from larger pharmaceutical companies.
For those seeking more details, the full press release is available at https://ibn.fm/XgpMR. Additionally, the latest news and updates relating to ONNVF can be found in the company's newsroom at https://ibn.fm/ONNVF. BioMedWire, the platform that hosted the podcast, is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, and is part of the Dynamic Brand Portfolio @ IBN, which delivers a vast network of wire solutions, article syndication to over 5,000 outlets, and social media distribution. For more information, visit https://www.BioMedWire.com.
Overall, Onco-Innovations' progress with ONC010 underscores the importance of continued research into novel cancer targets and the potential of nanotechnology to improve drug delivery. As the company moves toward clinical trials, the outcomes will be pivotal in determining whether ONC010 can fulfill its promise as a new weapon in the fight against cancer.
